5,296,209 Shares in Iovance Biotherapeutics, Inc. $IOVA Acquired by Palo Alto Investors LP

Palo Alto Investors LP bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,296,209 shares of the biotechnology company’s stock, valued at approximately $22,032,229. Iovance Biotherapeutics accounts for 0.0% of Palo Alto Investors LP’s portfolio, making the stock its 11th largest position. Palo Alto Investors LP owned approximately 1.17% of Iovance Biotherapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Corient Private Wealth LP acquired a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth $220,000. Bank of America Corp DE acquired a new stake in shares of Iovance Biotherapeutics in the 2nd quarter worth about $20,773,000. Freestone Grove Partners LP bought a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $178,000. Man Group plc purchased a new stake in Iovance Biotherapeutics during the 2nd quarter valued at $1,052,000. Finally, Jupiter Topco LLC purchased a new stake in Iovance Biotherapeutics during the 2nd quarter valued at $589,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Trading Down 3.0%

Shares of Iovance Biotherapeutics stock traded down $0.25 during trading hours on Friday, reaching $8.01. The stock had a trading volume of 7,682,580 shares, compared to its average volume of 15,682,115. The firm has a 50 day simple moving average of $5.39 and a two-hundred day simple moving average of $4.29. Iovance Biotherapeutics, Inc. has a 1 year low of $1.76 and a 1 year high of $9.36. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of -10.97 and a beta of 0.71.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.The business had revenue of $198.63 million for the quarter, compared to analyst estimates of $87.83 million. During the same period in the previous year, the company posted ($0.33) earnings per share. The firm’s revenue for the quarter was up 65.7% on a year-over-year basis. Sell-side analysts forecast that Iovance Biotherapeutics, Inc. will post -0.48 EPS for the current year.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Price target raised: Iovance’s price target was increased to $10.00, implying continued upside from recent trading levels and providing a potential catalyst for the stock. Iovance Biotherapeutics Price Target Raised to $10.00
• Positive Sentiment: Some earnings revisions improved: Zacks Research raised its Iovance EPS forecasts for the third quarter of 2026, full-year 2026, second quarter of 2027, second quarter of 2028 and full-year 2028. The FY2026 loss estimate improved from $0.62 to $0.56 per share, while the FY2028 loss estimate improved from $0.10 to $0.07, suggesting expectations for better profitability over time.
• Positive Sentiment: Sector interest: Iovance was highlighted among oncology companies benefiting from continued innovation in cancer treatments. The company’s focus on cell therapy could support investor interest in its commercial and pipeline opportunities. Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
• Neutral Sentiment: Forecasts remain mixed: Zacks lowered estimates for the first quarter of 2027, third and fourth quarters of 2027, full-year 2027 and first quarter of 2028, including a reduction in the FY2027 loss forecast from $0.36 to $0.44 per share. These cuts offset several of the improved estimates.
• Negative Sentiment: Profitability remains ahead, not immediate: Zacks still expects Iovance to report losses through the forecast period, including estimated losses of $0.56 per share in FY2026 and $0.44 in FY2027. Investors therefore remain dependent on revenue growth, commercial execution and clinical progress rather than near-term profits. Zacks Industry Outlook

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Barclays lifted their price objective on shares of Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. TD Cowen increased their target price on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Monday. Citizens Jmp boosted their price objective on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Mizuho boosted their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.89.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.